Novo Nordisk Initiates Post-Marketing Surveillance for Alhemo® in Haemophilia Patients
Novo Nordisk is conducting a post-marketing surveillance study on Alhemo® to assess its safety and effectiveness in real-world settings.
Phase III
Hematology / Haemophilia A/B
Status
Active
Sponsor
Novo Nordisk
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
Novo Nordisk's post-marketing surveillance of Alhemo® is significant as it aims to gather real-world data on its safety and effectiveness. The outcomes of this study could reshape competitive dynamics and influence treatment protocols in the haemophilia market.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor for interim results and final outcomes from the study over the next two years.
Related companies & assets
Companies
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.